| First Author | Tifft CJ | Year | 1997 |
| Journal | Ann Med | Volume | 29 |
| Issue | 6 | Pages | 557-61 |
| PubMed ID | 9562524 | Mgi Jnum | J:47488 |
| Mgi Id | MGI:1203541 | Doi | 10.3109/07853899709007482 |
| Citation | Tifft CJ, et al. (1997) The beta-hexosaminidase deficiency disorders: development of a clinical paradigm in the mouse. Ann Med 29(6):557-61 |
| abstractText | Tay-Sachs disease and Sandhoff disease are severe neurodegenerative disorders caused by a deficiency of beta-hexosaminidase A and resultant accumulation of its substrate, GM2 ganglioside, in neuronal lysosomes. The three clinical forms of the disorders (infantile, juvenile and adult) are of varying severity and onset, and have been correlated with the amount of residual GM2 ganglioside-degrading activity present in patients' cells. Through targeted disruption of the murine beta-hexosaminidase genes in embryonic stem cells, we have developed a set of mice that vary in their GM2 ganglioside-degrading capacity and exhibit many of the clinical features of the human diseases. These mice are valuable for the study of pathogenic mechanisms and for devising novel therapeutic strategies in these disorders. |
